Analyses / MRNA
Vaccine revenue cliff, negative margins, but strong balance sheet and insider buying signal potential inflection point.
A free account reveals MRNA's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Strong balance sheet (3.3x current ratio, $56.4B market cap); insider buying outpace selling; 5Y revenue CAGR +19.3% pre-cliff. RSV vaccine, flu/respiratory portfolio may re-accelerate growth. Trading 70% below 52w high signals capitulation.
▼ Bear Case
Revenue crashed -53% YoY; operating margin -158%, net margin -146%; P/S 29.6x (expensive despite collapse). mRNA pipeline execution risk. Near-term cash burn from R&D. Insider selling slightly outpaced buying (3.01M vs 2.93M shares).
Valuation
OVERVALUED on revenue basis, FAIR on balance-sheet basis — score 58/100
P/S 29.6x is expensive even for biotech in decline; negative margins and -53% YoY revenue collapse do not justify premium. However, P/B 1.33x and strong liquidity (3.3x current ratio) suggest asset value floor. Turnaround stories require patience; near-term cash burn and margin recovery unproven.
Technical Levels
Support · $135.00 (Today's low, intraday support) · $120.00 (Stop-loss; 16% downside from current) · $100.00 (1-year downside scenario; -30% from current)
Resistance · $150.00 (Today's high ($149.7344), near-term resistance) · $165.00 (3-month target; +15% from current) · $176.66 (52-week high; +23% from current)
RSI: N/A (not provided)
Financial Health
Score 76/100. Strong liquidity buffers (3.3x current ratio) provide runway for R&D and potential restructuring. Gross margin remains healthy at 70%, but operating and net margins are deeply negative, reflecting post-pandemic vaccine revenue collapse and ongoing R&D burn. Balance sheet does not indicate near-term solvency risk, but profitability recovery is critical over next 12–24 months.
Catalysts
| Q earnings release (date TBD from payload) | Next 1–2 quarters | high |
| RSV vaccine (Arexvy) uptake data / new indication approval | 12–18 months | high |
| Pipeline updates: mRNA cancer, other respiratory programs | Ongoing; key conferences (ASCO, AACR) + press releases | high |
| Margin stabilization / return to profitability guidance | 12–24 months | high |
| Fed rate decisions, biotech sector sentiment rotation | Ongoing | medium |
Risk Flags
See MRNA's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock MRNA free →Recent News
- Dow Jones Futures: Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting AheadYahoo
- Dow Jones Futures Fall, Techs Tumble As Anthropic Leads Call For AI Slowdown; Fed Meeting AheadYahoo
- Dow Jones Futures: Will Anthropic-Led Call For Slowdown Hit AI Stocks? Fed Meeting AheadYahoo
- Dow Jones Futures: AI Stocks In Focus As Anthropic's Amodei, OpenAI's Altman, SpaceX's Musk Call For AI SlowdownYahoo
- Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New BuysYahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full MRNA analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
MRNA FAQ
Is MRNA a buy right now?
Moderna Inc's current read is a recovery / turnaround setup with 52 confidence over a 6-12 months horizon. Valuation: OVERVALUED on revenue basis, FAIR on balance-sheet basis. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is MRNA overvalued?
OVERVALUED on revenue basis, FAIR on balance-sheet basis (valuation score 58/100). P/S 29.6x is expensive even for biotech in decline; negative margins and -53% YoY revenue collapse do not justify premium. However, P/B 1.33x and strong liquidity (3.3x current ratio) suggest asset value floor. Turnaround stories require patience; near-term cash burn and margin recovery unproven.
What are the risks of buying MRNA?
Revenue crashed -53% YoY; operating margin -158%, net margin -146%; P/S 29.6x (expensive despite collapse). mRNA pipeline execution risk. Near-term cash burn from R&D. Insider selling slightly outpaced buying (3.01M vs 2.93M shares).